Simulations Plus, Inc. (NASDAQ:SLP) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 330,100 shares, an increase of 27.6% from the June 30th total of 258,800 shares. Based on an average daily trading volume, of 134,800 shares, the short-interest ratio is currently 2.4 days. Approximately 2.7% of the company’s stock are sold short.
In other news, Director John Kenneth Paglia sold 690 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $37.86, for a total value of $26,123.40. Following the completion of the sale, the director now owns 2,112 shares in the company, valued at approximately $79,960.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Walter S. Woltosz sold 18,500 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $25.67, for a total transaction of $474,895.00. Following the completion of the sale, the director now owns 5,178,083 shares of the company’s stock, valued at approximately $132,921,390.61. The disclosure for this sale can be found here. Corporate insiders own 31.57% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Advisor Group Inc. boosted its holdings in Simulations Plus by 156.9% in the fourth quarter. Advisor Group Inc. now owns 2,112 shares of the technology company’s stock valued at $42,000 after acquiring an additional 1,290 shares in the last quarter. BNP Paribas Arbitrage SA boosted its holdings in Simulations Plus by 59,875.0% in the first quarter. BNP Paribas Arbitrage SA now owns 2,399 shares of the technology company’s stock valued at $51,000 after acquiring an additional 2,395 shares in the last quarter. Metropolitan Life Insurance Co. NY bought a new stake in Simulations Plus in the fourth quarter valued at $79,000. Oppenheimer Asset Management Inc. boosted its holdings in Simulations Plus by 5.9% in the second quarter. Oppenheimer Asset Management Inc. now owns 4,783 shares of the technology company’s stock valued at $137,000 after acquiring an additional 265 shares in the last quarter. Finally, MetLife Investment Advisors LLC bought a new stake in Simulations Plus in the fourth quarter valued at $108,000. Hedge funds and other institutional investors own 41.26% of the company’s stock.
SLP traded down $0.38 on Monday, reaching $37.66. The company had a trading volume of 170,224 shares, compared to its average volume of 86,471. The business has a 50 day moving average of $33.63. The stock has a market capitalization of $696.70 million, a P/E ratio of 75.32 and a beta of -0.35. Simulations Plus has a 52-week low of $17.18 and a 52-week high of $41.95.
Simulations Plus (NASDAQ:SLP) last announced its earnings results on Wednesday, July 10th. The technology company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. The business had revenue of $9.94 million for the quarter, compared to the consensus estimate of $9.85 million. Simulations Plus had a net margin of 24.09% and a return on equity of 23.48%. Equities research analysts anticipate that Simulations Plus will post 0.46 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Thursday, July 25th were issued a $0.06 dividend. This represents a $0.24 annualized dividend and a dividend yield of 0.64%. The ex-dividend date of this dividend was Wednesday, July 24th. Simulations Plus’s dividend payout ratio is 48.00%.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Recommended Story: How mutual funds make money
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.